Advisory Role
Kazmira Therapeutics’ Medical & Scientific Advisors provide independent guidance on scientific standards, evidence interpretation, and clinical context related to cannabinoid research and regulated healthcare applications. Advisory activities are limited to scientific review and educational input; advisors do not prescribe, dispense, provide patient care, or influence commercial, pharmacy, or operational decisions for Kazmira Therapeutics.
Some advisors are also licensed clinicians who provide patient care through independent healthcare platforms, including Cope Now. Any such clinical services are performed solely in their individual professional capacity and are operationally and clinically separate from their advisory role with Kazmira Therapeutics. Kazmira Therapeutics does not direct or control clinical decision-making
Dr. Rachit Marwaha, MD
Dr. Rachit Marwaha
Dr. Rachit Marwaha is a physician trained in internal medicine and interventional pain management, with experience across primary care and complex medical conditions.
Dr. Marwaha received his medical degree from St. George’s University School of Medicine and completed his internal medicine residency at NewYork-Presbyterian Methodist Hospital in Brooklyn, New York. His clinical background informs his advisory perspective on patient populations, care pathways, and the practical considerations required for therapies to function within real-world healthcare settings.
As a Medical & Scientific Advisor to Kazmira Therapeutics, Dr. Marwaha contributes clinical context and perspective to the evaluation of scientific literature and emerging evidence related to non-intoxicating cannabinoids, without participating in treatment decisions or patient care.
Dr. Gautham Oroskar, MD
Dr. Gautham Oroskar
Dr. Gautham Oroskar is a board-certified internal medicine physician practicing hospital-based medicine in the Chicago area. He received his medical degree from Chicago Medical School at Rosalind Franklin University of Medicine and Science
Dr. Oroskar has conducted basic science research focused on gut dysbiosis in metabolic disease and has experience reviewing clinical literature across a range of medical conditions. His background includes evaluating scientific data and study design relevant to translational and clinical research contexts.
In his advisory role with Kazmira Therapeutics, Dr. Oroskar contributes to scientific literature review and evidence assessment related to cannabidiol (CBD) research, supporting disciplined interpretation of available data within regulated healthcare frameworks.
